Unkrautvernichter: Bayer gewinnt Glyphosat-Prozess – Aktie steigt vorbörslich
Der Prozess ist der zweite innerhalb weniger Monate, den Bayer in der Cause Glyphosat gewonnen hat. Bei einer weiteren Klage steht ein Urteil noch aus. Für Bayer geht es um Milliarden.
A jury in Missouri unanimously ruled in favor of Bayer in a glyphosate trial on the night of Thursday. After the pharmaceutical and agrochemical giant won a landmark glyphosate case in June, this Missouri trial was significant as plaintiffs presented different arguments against Bayer. The company's stock price rose about four percent on the Tradegate pre-market trading platform compared to Xetra's close.
Following the Supreme Court's ruling, Bayer is now shielded from further lawsuits claiming inadequate cancer warnings on Roundup weed killer packaging. In this concluded trial in St. Louis, the plaintiffs had argued instead that Roundup was poorly designed and plaintiffs were deliberately deceived. Their victory in court is expected to bolster Bayer's efforts to largely dispel the glyphosate causation, which has cost the company billions.
The focus now shifts to an ongoing judicial decision on its settlement agreement, under which Bayer will make decreasing, capped annual payments totaling up to $7.25 billion over 21 years.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Technology Group: Microsoft starts strongly into the new fiscal year handelsblatt.com
